JPRN-UMIN000016387招募中4 期
Special Drug Use Surveillance of LIXIANA Tablet- Long-term use in patients with venous thromboembolism
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who meet the following requirements when starting to receive LIXIANA (at the time of enrollment for [3]) will be considered for admission to the study:
- •[1] Patients who have just started to receive LIXIANA for the first time for the treatment and secondary (recurrence) prevention of VTE (DVT and PTE)
- •[2] Patients who are to start treatment with LIXIANA during the period of contract (as per the signed contract between the institution and the sponsor) and during the enrollment period
- •[3] Patients who have given written informed consent to the study
排除标准
- 未提供
研究者
相似试验
招募中
4 期
Special Drug Use Surveillance of LIXIANA Tablet- Long-term use in patients with non-valvular atrial fibrillationPrevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation.JPRN-UMIN000017011DAIICHI SANKYO COMPANY, LIMITED10,000
招募中
不适用
Special drug use Surveillance for EFIENT Tablets- Patient with ischemic cerebrovascular disease with a high risk of ischemic strokeIschemic cerebrovascular disease (associated with large-artery atherosclerosis or small-vessel occluJPRN-jRCT2031220131Matsuoka Yomei1,200
招募中
不适用
Special Drug Use Surveillance of Alecensa Capsules in Pediatric Patients- Recurrent or refractory ALK fusion gene-positive anaplastic large cell lymphomaRecurrent or refractory ALK fusion gene-positive anaplastic large cell lymphomaJPRN-UMIN000039803Chugai Pharmaceutical Co. Ltd.10
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660
招募中
Unknown
Post-marketing Surveillance Protocol Number;CLCZ696A1402HypertensionJPRN-jRCT2031230283Sugigmoto Toshiya1,000